Mirza Nadeem Q. 4
4 · Aprea Therapeutics, Inc. · Filed May 2, 2024
Insider Transaction Report
Form 4
Mirza Nadeem Q.
Chief Medical Officer
Transactions
- Award
Common Stock
2024-05-01+6,730→ 6,730 total - Award
Stock Options (Right to Purchase)
2024-05-01+26,920→ 26,920 totalExercise: $5.25Exp: 2034-05-01→ Common Stock (29,920 underlying)
Footnotes (2)
- [F1]These shares were granted by the Issuer as an inducement material to the Reporting Person entering into employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4). These shares represent restricted stock units ("RSUs") and shall vest and be settled in the Issuer's common stock, on a one-for-one basis in three (3) equal annual installments beginning on May 1, 2025, until vested in full, subject to the Reporting Person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
- [F2]The option was granted by the Issuer as an inducement material to the Reporting Person entering into employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4). Twenty-five percent of these options vest on May 1, 2025, with the remaining options vesting ratably over the following 36 months, subject to the Reporting Person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.